(lp0
S'Market: The Regeneron Pharmaceuticals, Inc.  Position Maintained by ... Petro Global News 24 - Jan 25, 2017 A number of other hedge funds and other institutional investors have also modified their holdings of the company. IFP Advisors Inc boosted its stake in Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of ...'
p1
aS'Regeneron Pharmaceuticals Inc  Receives Average Recommendation of &quot;Hold ... The Cerbat Gem - 4 hours ago Regeneron Pharmaceuticals logo Shares of Regeneron Pharmaceuticals Inc  have received a consensus recommendation of Hold from the twenty-five analysts that are covering the firm.Raymond James Trust N.A. Purchases 70 Shares of Regeneron Pharmaceuticals Inc ... - BNB Daily Regeneron Pharmaceuticals Inc  Given Hold Rating at BMO Capital Markets - BBNS'
p2
aS"Regeneron Announces Evinacumab has Received FDA Breakthrough Therapy ... PR Newswire  - Apr 6, 2017 TARRYTOWN, N.Y., April 6, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.  today announced that the U.S.Regeneron's evinacumab a Breakthrough Therapy for inherited cholesterol disorder - Seeking AlphaRegeneron Pharmaceuticals Inc  Gets FDA's Breakthrough Therapy ... - Stock Market Daily"
p3
aS"A Review Of Certain Regeneron Patent Issues Seeking Alpha - Apr 5, 2017 In the field of pharmaceuticals and other patent-rich sectors of the economy, freedom to operate  is of paramount importance. Leaving aside REGN's first approved drug, Arcalyst, every one of its 5 other ..."
p4
aS'A Deep Dive Into Dupixent, From Regeneron-Sanofi Seeking Alpha - Mar 30, 2017 A breakthrough treatment for extensive eczema, aka atopic dermatitis, has now been approved by the FDA. The drug, Dupixent, was developed by Regeneron in partnership with Sanofi, and is expected to gain other indications, most notably for refractory&nbsp;...Drugmakers Are Trying a New Strategy: Charging Less - BloombergRegeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXENT ... - PharmiWeb.com '
p5
aS'Regeneron and Sanofi Announce FDA Approval of DUPIXENT , the First ... PR Newswire  - Mar 28, 2017 TARRYTOWN, N.Y. and PARIS, March 28, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.  and Sanofi today announced that the U.S.FDA approves Regeneron, Sanofi $37000 per year eczema drug - ReutersCredit Suisse Updated its Pricing Model for Regeneron Pharmaceuticals Inc  - Smrt Stck Nws'
p6
aS'Regeneron to Report First Quarter 2017 Financial and Operating Results and ... PR Newswire  - Apr 14, 2017 TARRYTOWN, N.Y., April 14, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.  today announced that it will report its first quarter 2017 financial and operating results on Thursday, May 4, 2017, before the U.S.Regeneron Pharmaceuticals Inc  Rating Reiterated by Jefferies Group LLC - The Cerbat GemGulf International Bank UK Ltd Has $9.321 Million Stake in Regeneron ... - BNB Daily '
p7
aS'Regeneron Pharmaceuticals Inc Risk Points versus Health Care CML News - Apr 6, 2017 This is a scatter plot analysis of the critical risk points from the option market for Regeneron Pharmaceuticals Inc  compared to its own past and the Health Care ETF.'
p8
aS'Traders Take Note: Regeneron Pharmaceuticals Inc  Stock Drops ... CML News - 22 hours ago Take Note: Regeneron Pharmaceuticals Inc  has hit some technical weakness in its momentum, and while it has not broken down all the way through support -- watch the key levels that we discuss below and further, watch the stochastics&nbsp;...'
p9
aS'Regeneron Pharmaceuticals Inc.  Rises 3.03% for March 29 Equities.com - Mar 29, 2017 Starting the day trading at $382.46, Regeneron Pharmaceuticals Inc. reached an intraday high of $401.21 and hit intraday lows of $382.06.Regeneron Pharmaceuticals Inc  PT Set at $446.00 by Piper Jaffray Companies - The Cerbat GemDigging Up the Facts on Regeneron Pharmaceuticals, Inc.  - StockNewsJournal'
p10
a.